|
業務類別
|
Biotechnology |
|
業務概覽
|
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2. |
| 公司地址
| 6200 Lookout Road, Boulder, CO, USA, 80301 |
| 電話號碼
| +1 720 647-8519 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.enliventherapeutics.com |
| 員工數量
| 60 |
| Mr. Benjamin Hohl |
Chief Financial Officer, Principal Accounting Officer and Head,Corporate Development |
美元 480.00K |
27/04/2026 |
| Mr. Sam Kintz, M.B.A. |
Head of Pipeline |
美元 624.15K |
11/12/2025 |
| Dr. Helen Collins, M.D. |
Chief Medical Officer |
美元 523.00K |
27/04/2026 |
| Mr. Richard A. Fair |
Director, President and Chief Executive Officer |
美元 38.08K |
27/04/2026 |
|
|
| Dr. Rahul D. Ballal, PhD |
Independent Director |
27/04/2026 |
| Dr. Lori Anne Kunkel, M.D. |
Independent Director |
27/04/2026 |
| Dr. Mika Derynck, M.D. |
Independent Director |
27/04/2026 |
| Dr. Richard Heyman, PhD |
Chairman of the Board |
27/04/2026 |
| Mr. Jacob Bauer, M.B.A. |
Independent Director |
27/04/2026 |
| Mr. Rishi Gupta, J.D. |
Independent Director |
27/04/2026 |
| Mr. Richard A. Fair |
Director, President and Chief Executive Officer |
27/04/2026 |
| Mr. Scott Garland |
Director |
07/01/2026 |
|
|
|
|
